To include your compound in the COVID-19 Resource Center, submit it here.

MGD011: Phase I started

Johnson & Johnson’s Janssen Biotech Inc. unit began an open-label, dose-escalation, dose-expansion, international

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE